eFFECTOR Therapeutics News

EFFECTOR Therapeutics to Participate in Upcoming Investor Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitor

GlobeNewswireApr 9 08:00 ET

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), UniQure (QURE) and EFFECTOR Therapeutics (EFTR)

TipRanksApr 8 22:20 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersCandel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutics (NASDAQ:GALT) share

BenzingaApr 5 12:31 ET

Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)

TipRanksApr 5 06:30 ET

Trending Stocks Today: Candel Therapeutics Shoots up 121.64%

April 4th - US stocks trending in regular trading hours.Gainers: $Candel Therapeutics(CADL.US)$ shoots up 121.64% to $3.72 with a turnover of $214.01 million. $Allurion Technologies(ALUR.US)$ surges 9

moomoo NewsApr 4 14:00 ET

Top Midday Decliners

eFFECTOR Therapeutics (EFTR) Chief Executive Officer Steve Worland said there is no "obvious path forward to continue developing tomivosertib in frontline NSCLC" based on the data currently available

MT NewswiresApr 4 13:54 ET

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%

BenzingaApr 4 13:21 ET

BRNS, UPC and KWE Among Mid-day Movers

Seeking AlphaApr 4 13:06 ET

Effector Therapeutics Shares Plumb New Depths After Study Failure

By Colin Kellaher Effector Therapeutics shares collapsed on Thursday, tumbling 80% and hitting a new all-time low, after the clinical-stage biopharmaceutical company reported the failure of its lead

WSJApr 4 12:48 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersCandel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. TC BioPharm (Holdin

BenzingaApr 4 12:31 ET

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P

BenzingaApr 4 11:58 ET

Cancer-Focused EFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

Thursday, eFFECTOR Therapeutics Inc (NASDAQ:EFTR) released topline results from the primary analysis of the Phase 2 KICKSTART trial, which tested tomivosertib or placebo, each combined with Merck & Co

BenzingaApr 4 10:38 ET

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ

BenzingaApr 4 10:02 ET

Express News | EFFECTOR Therapeutics Shares Resume Trade

Moomoo 24/7Apr 4 09:52 ET

Express News | EFFECTOR Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83.2%

Moomoo 24/7Apr 4 09:49 ET

Express News | EFFECTOR Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From the Primary Analysis of the Randomized Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-small Cell Lung Cancer

Moomoo 24/7Apr 4 09:17 ET

EFFECTOR Therapeutics to End Development of Lung-Cancer Treatment Tomivosertib

By Adriano Marchese EFFECTOR Therapeutics said Thursday that it won't be moving forward with development of its tomivosertib lung cancer treatment after phase 2 data showed no positive trend. The ca

WSJApr 4 08:58 ET

Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Moomoo 24/7Apr 4 08:55 ET

EFFECTOR Therapeutics to Resume Trading at 9 A.m. Following Disappointing Tomivosertib Data in NSCLC

InvestingApr 4 08:50 ET

EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-Small Cell Lung Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the

GlobeNewswireApr 4 08:30 ET